Start here if you're new
what it is
Philips sells hospital imaging gear, patient monitoring systems, and personal health products like electric toothbrushes and shavers.
how it gets paid
Last year Koninklijke Philips made $20.5B in revenue. Diagnosis & Treatment was the main engine at $9.2B, or 49% of sales.
what just happened
The story is simple: Philips went from a $0.94 per-share loss in 2024 to $1.60 of profit in 2025.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
15/100 earnings predictability — expect surprises
18.3x trailing p/e — priced about right
3.6% dividend yield — cash in your pocket every quarter
8.2% return on capital — nothing to write home about
xvary composite: 49/100 — below average
What they do
Philips sells hospital imaging gear, patient monitoring systems, and personal health products like electric toothbrushes and shavers.
Philips wins because hospitals do not swap out imaging and monitoring systems casually. Diagnosis & Treatment and Connected Care were 78% of 2024 sales, according to the company breakdown in the research note. R&D was 9.7% of sales in 2024, which means you are not betting on a logo, you are betting on a product pipeline that hospitals already know.
How they make money
$20.5B
annual revenue
Diagnosis & Treatment
$9.2B
Connected Care
$5.4B
Personal Health
$3.6B
Other
$0.6B
The products that matter
global healthcare technology business
Healthcare technology
$20.5B annual revenue · 9.2% net margin
the segment detail is thin on this page, so the right read is high level: this is a $20.5B business that keeps about 9 cents of every revenue dollar. big enough to matter. not efficient enough to get a free premium.
execution matters
licensed technology and intellectual property
Licensing
data detail limited
licensing shows up in the source data, but the revenue split does not. when the dataset is thin, the honest move is to say so. you need the full segment mix before calling any part of Philips the growth engine.
thin disclosure here
Key numbers
$1.60
2025 EPS
Earnings per share → profit for each share → so what: Philips went from losing money in 2024 to making money in 2025.
18.3x
trailing p/e
P/E → price divided by earnings → so what: you are paying a mid-pack multiple for a company still proving the turnaround is real.
16.0%
operating margin
Operating margin → profit after running the business → so what: Philips keeps $16 on every $100 of sales before interest and taxes.
3.6%
dividend yield
Dividend yield → cash paid to shareholders each year → so what: you get paid while management tries to make the turnaround look less temporary.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- long-term debt $8.5B (23% of capital)
- net profit margin 9.2% — keeps 9 cents of every dollar in revenue
- return on equity 13% — $0.13 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in PHG 3 years ago → it's now worth $19,280.
The index would have given you $14,770.
source: institutional data · total return
What just happened
returned to profit
The story is simple: Philips went from a $0.94 per-share loss in 2024 to $1.60 of profit in 2025.
Every 2025 quarter was profitable, versus two loss quarters in 2024. The research note says efficiency moves and faster Personal Health growth helped close out 2025 on solid footing.
$1.60
2025 eps
$0.49
q4 2025 eps
-$0.94
2024 eps
the number that mattered
The number that mattered was $1.60, because it turned a loss-making 2024 into a profitable 2025 and made the turnaround look operational, not cosmetic.
-
recent performances have been fueled by benefits from efficiency initiatives and accelerated growth in its personal health business (september-period sales +11% vs. prior year), which have helped to mitigate increased competitive pressures, tariff-related headwinds, and lingering weakness in china.
-
all in all, we believe that philips closed out 2025 on solid footing.
-
our model calls for continued top- and bottom-line improvement in 2026.the company is at the tail end of a multi-year turnaround strategy aimed at streamlining operations, boosting profitability, and improving patient safety following major product recalls. core components of the plan included significant headcount reductions, refining the organization into three core segments (diagnosis & treatment, connected care, and personal health), and expanding its ai-driven portfolio.
-
execution of these initiatives produced tangible results during the course of 2025, and in our view, puts phillips in a favorable position for continued bottom-line expansion this year and next.
-
leadership is expected to provide its 2026-2028 strategy on the upcoming conference call.we anticipate the company will highlight the need for further investment in health-tech innovation, with a significant emphasis on ai-enabled imaging, diagnostic viewers, and clinical decision tools. other core components will likely include maintaining operational efficiency, margin expansion initiatives, and perhaps an increased focus on international markets. countries like india and saudi arabia are reportedly investing heavily in healthcare infrastructure and digitization and could represent more lucrative opportunities for philips.
source: quarterly EPS history, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is the legal overhang tied to the 2021 securities-fraud investigation headline around Philips disclosures.
med
old litigation headlines can keep the discount alive
On Jun 22, 2021, Glancy Prongay & Murray LLP announced an investigation involving Koninklijke Philips N. That headline is old, but legal overhangs do not disappear just because the calendar moved on.
this matters because a stock on 18.3x earnings and a 49/100 composite score does not have much room for trust shocks.
med
better orders still have to become better economics
The Nov 4, 2025 headline on stronger order intake is encouraging. It is not enough by itself. Philips still posts just 8.2% return on capital and 15/100 earnings predictability.
if those orders do not lift profitability, the stock stays a recovery trade rather than a quality compounder.
med
analyst target data does not scream upside
The listed 3–5 year midpoint is $26 versus a current price of $29.24. Even before you debate the assumptions, that tells you the base case is not obviously cheap.
when current price sits above the midpoint target, you need execution beats, not just decent results.
med
thin segment detail makes the story harder to underwrite
This page has $20.5B of total revenue, but no useful segment split. That means you cannot cleanly isolate what part of Philips is driving growth, margin, or risk from this snapshot alone.
less transparency raises the burden of proof. you should want cleaner segment evidence before paying up.
four risks stand out: legal overhang, execution risk, limited base-case upside, and thin segment transparency. together they explain why a stable balance sheet still earns only a 49/100 composite.
source: institutional data · regulatory filings · risk analysis
Pay attention to
trend
institutions have been net buyers for 3 straight quarters
150 buyers versus 105 sellers in 3q2025 is real demand. if that streak breaks, the support under the recovery story gets thinner.
metric
15/100 earnings predictability is the number that matters
In human-speak: Philips still does not produce the kind of clean, repeatable numbers that markets usually reward with premium multiples.
calendar
the next checkpoint is whether Philips can earn into the $1.90 fy2027 estimate
That estimate is the bridge between a merely okay 18.3x p/e and a stock that can justify staying near the top of its $22–$30 range.
risk
current price already sits above the $26 midpoint target
You do not usually call that a screaming bargain. if the operating improvement stalls, valuation stops helping you.
Analyst rankings
earnings predictability
15 / 100
in human-speak, analysts do not see Philips as a clean forecast story yet.
risk rank
3
safer than about 50% of stocks. not reckless, not exactly defensive either.
xvary composite
49 / 100
the market sees enough to stay interested, but not enough to hand Philips the benefit of the doubt.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 150 buyers vs. 105 sellers in 3q2025. total institutional holdings: 48.8M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$16
$35
$29
current price
$26
target midpoint · 11% from current · 3-5yr high: $45 (+55% · 14% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive